Business
PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics
PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics.
About this update from Tron Group Inc.
[{"type":"text","content":" https://news.lifesciencenewswire.com/newsroom/precisionlife-announces-strategic-cns-drug-development-collaboration-with-nanopharmaceuticsCollaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio.Agreement to utilize PrecisionLife’s combinatorial analytics platform to identify genetic biomarkers that will optimize patient selection across multiple CNS clinical trials.Oxford, UK, and Alachua, US, 15 June 2023 – PrecisionLife, a leading techbio company driving precision medicine into complex chronic diseases, and Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, announced today a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of central nervous system (CNS) assets.The collaboration will leverage PrecisionLife’s proprietary combinatorial analytics platform to analyze patient genomic profiles and identify target-specific genetic biomarkers for each of Nanopharmaceutics’ CNS drug development programs. These biomarkers will be based on combinations of single nucleotide polymorphisms (SNPs) specifically associated with Nanopharmaceutics’ drugs’ mechanisms of action and the development indication.As part of the collaboration, PrecisionLife will support Nanopharmaceutics in the clinical development of their CNS programs by identifying patient stratification biomarkers to link the development compounds’ mechanisms of action to the patient subgroups with the highest likelihood of demonstrating positive outcomes in clinical trials, optimizing patient selection. The terms of the collaboration also include an option for Nanopharmaceutics to negotiate an exclusive right to the patient stratification biomarkers discovered through the PrecisionLife platform.This precision medicine approach has the potential to significantly increase the probability of clinical trial success rates, even in the most complex chronic diseases. Beyond the applications set out in this collaboration, PrecisionLife biomarkers may also serve as invaluable complementary diagnostic tools, expediting the approval of new therapeutic products and facilitating the swift delivery of the latest medicines to patients with unmet medical needs.Commenting on the collaboration, James Talton, PhD, President and CEO of Nanopharmaceutics, stated: \"We're thrilled t...